Metabolon : Biochemical Understanding of Alzheimers Disease

October 13, 2010 — Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of “Ablation of the Locus Coeruleus (LC) Increases Oxidative Stress in Tg-2576 Transgenic But Not Wild-type Mice” in the International Journal of Alzheimer Disease. The paper examines the role of the LC on markers of oxidative stress in transgenic mice and was carried out as a collaboration among scientists at Pfizer, Proteostasis Therapeutics, the University of Dundee, Duke University and Metabolon. The paper is co-authored by Orest Hurko, Kurt Boudonck, Cathleen Gonzalez, J. Steve Jacobsen, Peter H. Reinhart, Crowther Daniel, Zoe A. Hughes.

Previous research in this area suggested that differences in inflammatory response observed in humans with Alzheimer disease and mouse models reflect a discrepancy in the state of the LC, the major site of norepinephrine synthesis in the brain. LC degeneration is an early change in human Alzheimer disease, but it is preserved in transgenic mouse models of Alzheimer disease... Metabolon's Press Release -

Proteostasis Therapeutics: Paper in Cell Establishing Role of the Proteostasis Network in Alzheimer's Disease

December 15, 2009 - Proteostasis Therapeutics announced that modulating a key Proteostasis Network (PN) pathway may offer a novel approach to Alzheimer’s disease, a finding that was published in the journal Cell by its scientific founders Andrew Dillin, Ph.D., and Jeffery Kelly, Ph.D. The publication describes how regulation of an aggregase pathway reduced the neurodegenerative effects of beta amyloid aggregates that are a hallmark of the disease. Proteostasis has exclusively licensed the intellectual property for modulating this pathway from the Salk Institute and is integrating it into its proprietary technology platform directed to the discovery of a new class of therapeutics, Proteostasis Regulators (PR), small molecules designed to correct defects in the PN... Proteostasis Therapeutics' Press Release -